NADAC acquisition cost data for OPZELURA 1.5% CREAM. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 50881000705 | $31.24 | 2022-06-22 | Rx |
| 50881000705 | $31.24 | 2022-06-22 | Rx |
| 50881000705 | $31.24 | 2022-06-22 | Rx |
| 50881000705 | $31.24 | 2022-06-22 | Rx |
| 50881000705 | $31.24 | 2022-06-22 | Rx |
| 50881000705 | $31.24 | 2022-06-22 | Rx |
| 50881000705 | $31.24 | 2022-06-22 | Rx |
| 50881000705 | $31.24 | 2022-06-22 | Rx |
| 50881000705 | $31.24 | 2022-06-22 | Rx |
| 50881000705 | $31.24 | 2022-06-22 | Rx |
Generic: Ruxolitinib Phosphate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A |
| 2021 | $946.8K | 461 | 382 | $33.50 |
| 2022 | $24.3M | 11,447 | 6,243 | $33.78 |
| 2023 | $75.7M | 33,784 | 14,085 | $35.11 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $18.2M | 7,891 | 3,127 |
| California | $12.8M | 5,770 | 2,366 |
| Florida | $5.3M | 2,483 | 1,123 |
| Texas | $3.6M | 1,656 | 739 |
| New Jersey | $2.6M | 1,121 | 454 |
| Ohio | $2.5M | 1,122 | 448 |
| Massachusetts | $2.3M | 1,011 | 446 |
| North Carolina | $2.1M | 920 | 411 |
| Pennsylvania | $1.8M | 828 | 336 |
| Connecticut | $1.7M | 707 | 304 |
| Georgia | $1.6M | 734 | 362 |
| Maryland | $1.5M | 718 | 327 |
| Colorado | $1.4M | 591 | 259 |
| Michigan | $1.3M | 601 | 240 |
| Illinois | $1.3M | 568 | 242 |
| Arizona | $1.1M | 477 | 210 |
| Virginia | $1.1M | 471 | 209 |
| Louisiana | $1.0M | 461 | 190 |
| South Carolina | $944.9K | 450 | 195 |
| Tennessee | $847.2K | 356 | 142 |
| Alabama | $828.4K | 385 | 172 |
| Indiana | $798.5K | 355 | 163 |
| Wisconsin | $774.9K | 344 | 159 |
| Missouri | $731.1K | 319 | 122 |
| Hawaii | $718.7K | 342 | 169 |
| Washington | $681.9K | 279 | 148 |
| Minnesota | $584.9K | 248 | 97 |
| Nevada | $540.1K | 241 | 94 |
| Iowa | $400.8K | 178 | 69 |
| Kentucky | $367.7K | 169 | 80 |
| Kansas | $367.3K | 171 | 56 |
| Mississippi | $347.3K | 157 | 59 |
| Oregon | $330.2K | 137 | 61 |
| New Mexico | $314.8K | 151 | 63 |
| Alaska | $255.0K | 74 | 30 |
| Nebraska | $239.3K | 114 | 46 |
| New Hampshire | $238.5K | 109 | 41 |
| Oklahoma | $233.2K | 113 | 58 |
| District of Columbia | $231.2K | 95 | 34 |
| Puerto Rico | $222.9K | 109 | 54 |
| Arkansas | $220.1K | 102 | 45 |
| Rhode Island | $192.7K | 90 | 65 |
| Maine | $192.2K | 82 | 36 |
| Utah | $177.4K | 84 | 48 |
| Montana | $170.1K | 80 | 24 |
| West Virginia | $154.0K | 67 | 22 |
| Delaware | $141.9K | 62 | 32 |
| Idaho | $137.3K | 60 | 38 |
| South Dakota | $119.0K | 56 | 24 |
| Vermont | $97.5K | 23 | 12 |
| North Dakota | $42.3K | 18 | N/A |
| Wyoming | $28.6K | 14 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.